OSE Immunotherapeutics secures its General Meeting

Nantes-based OSE Immunotherapeutics emphasizes its commitment to holding its Annual General Meeting in a transparent and respectful manner. With this in mind, a "Questions and Answers" document has been published online to inform shareholders of recent developments and address misinformation circulating in the market.

In response to resolutions from certain parties seeking to amend the Board of Directors, the General Meeting, initially scheduled for June 25, 2025, was postponed by court order. The new date is September 30, 2025, subject to judicial developments.

Furthermore, OSE Immunotherapeutics has taken legal action to maintain transparency and adherence to market rules, thereby ensuring a constructive exchange with all shareholders during this period of heightened tensions.